Biotest Balance Sheet Health
Financial Health criteria checks 3/6
Biotest has a total shareholder equity of €375.1M and total debt of €534.0M, which brings its debt-to-equity ratio to 142.4%. Its total assets and total liabilities are €1.1B and €734.7M respectively.
Key information
142.4%
Debt to equity ratio
€534.00m
Debt
| Interest coverage ratio | n/a |
| Cash | €115.30m |
| Equity | €375.10m |
| Total liabilities | €734.70m |
| Total assets | €1.11b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0N6Z's short term assets (€523.9M) exceed its short term liabilities (€114.9M).
Long Term Liabilities: 0N6Z's short term assets (€523.9M) do not cover its long term liabilities (€619.8M).
Debt to Equity History and Analysis
Debt Level: 0N6Z's net debt to equity ratio (111.6%) is considered high.
Reducing Debt: 0N6Z's debt to equity ratio has increased from 103.5% to 142.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 0N6Z has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 0N6Z is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 18.2% per year.